Wednesday, January 27, 2021 7:25:00 PM
"NeuroRx has arranged with the Nephron pharmaceutical group to initiate scaleup of aviptadil acetate 100µg/ml in saline. Pending review of the clinical data, NeuroRx is prepared to order the first 10,000 patient courses of treatment in the first quarter of 2021. At 1,500µg aviptadil per treatment kit, NeuroRx would have sufficient drug product in hand to supply 10,000 kits. NeuroRx has contracted with Bachem to supply 1 KG of Aviptadil during the first quarter of 2021, and glass syringes would be supplied by Nephron to support this order. NeuroRx has sufficient API on order to meet two years of supply at 100,000 patient doses per quarter. "
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
